Breakthroughs in identifying tumor biomarkers in liver, gastric, prostate, lung and other cancers and are accelerating ...

Nanostics Inc., a precision health company advancing diagnostic innovation through its ClarityDX® platform, today announced the publication of a peer-reviewed study in npj Digital Medicine validating ...

The MarketWatch News Department was not involved in the creation of this content. EDMONTON, AB, April 20, 2026 /PRNewswire/ - Nanostics Inc., a precision health company advancing diagnostic innovation ...

Objectives While exercise adherence is known to vary during cancer treatment, little is known about what predicts these changes during chemotherapy or within individual treatment cycles for breast ...

Highest death risk for SCLC, pancreatic cancer, but not reflected in average funding per d ...

Highl ights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth ...

THE VIBRANT city of London, UK, set the stage for Europe’s leading urological gathering this year: the 41st Annual European ...

Pfizer to showcase oncology innovation and next-generation pipeline at ASCO 2026: New York Friday, April 24, 2026, 10:00 Hrs [IST] Pfizer Inc. will present new data across its div ...

Application includes updated TRUST-I TKI-naïve median duration of response (mDOR) and median progression-free survival (mPFS) of more than 4 years, as well as TRUST-II ...

Biocon has received a Notice of Compliance from Health Canada for Bosaya (denosumab) and Vevzuo (denosumab), both biosimilars referencing Prolia and Xgeva, respectively. The approval covers Bosaya in ...

Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in ...